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life years saved, and the incremental cost effectiveness ratio.
Only direct medical costs in 2003 United States dollars were 
considered.
Implementation Strategy: A model was built based on the fol-
lowing assumptions: standard of care chemotherapy for previ-
ously untreated metastatic colorectal cancer was considered to
be 5-FU plus leucovorin plus either oxaliplatin (FOLFOX) or
irinotecan (FOLFIRI); improvement in median overall survival,
time to progression, and increased incidence of adverse events
with the addition of bevacizumab was based on published trials;
duration of treatment was equal to time to progression; cost of
therapy beyond disease progression was not included in the cost
effectiveness or budget impact analyses; and budget impact
analysis was based on the assumption that 40% of those patients
initially presenting with metastatic colorectal receive treatment
at UT M.D. Anderson Cancer Center (50% on FOLFOX and
50% on FOLFIRI). Non FDA-indicated use of bevacizumab was
not included in the budget impact analysis.
Direct medical costs of treatment with FOLFOX are
$140,114, and $270,049 for FOLFOX/bevacizumab, incremen-
tal cost of bevacizumab is $129,935. Comparable numbers are
$68,519 for FOLFIRI, and $165,330 for FOLFIRI/bevacizumab,
incremental cost is $96,811. Using published outcomes mea-
surements of 0.39 life years saved (LYS) with the addition of
bevacizumab to either FOLFOX or FOLFIRI, the incremental
cost effectiveness ratio was $333,167 per life year saved for the
FOLFOX and $248,233 per LYS for FOLFIRI. For our expected
annual patient population of 250, the annual budget impact of
chemotherapy and bevacizumab for our institution was pro-
jected to be $25,804,250.
This model, along with a clinical monograph, was presented
to the P&T Committee at the same time as the vote for beva-
cizumab’s inclusion onto formulary. Bevacizumab was added to
the formulary without restriction for its use with regards to its
FDA-indication.
Results: We reviewed MDACC usage for the ﬁrst six months of
2006. We had 411 unique patients, with 237 (60%) receiving
the drug for a gastrointestinal (GI) malignancy. Of these 237 GI
patients, there were 185 unique patients (78%) who received
bevacizumab for colorectal cancer, of which only 132 patients
(71%) received 5-FU/leucovorin plus bevacizumab plus either
oxaliplatin or irinotecan. This means that out of the 411 unique
patients who received bevacizumab at MDACC, only 132
patients (32%) actually used it in the manner our model detailed.
In order to estimate the accuracy of our model, we used these
132 patients as the basis to check our model’s validity and accu-
racy. For colo-rectal cancer patients receiving bevacizumab
added to either FOLFOX or FOLFIRI regimens, our model is
accurate to within 5% ($26.4M, actual versus $25.2M, model).
However, there are some caveats to the institution-wide valid-
ity of the model. We multiplied the number of patients actually
seen in the ﬁrst six months by two to estimate an annual number.
Our model excludes 279 patients (68%) who did not receive
bevacizumab for colo-rectal cancer. Determining the institutional
reimbursement pattern for the patients who received beva-
cizumab is ongoing.
Lessons Learned: For any drug that shows an improvement in
overall survival for a solid tumor, we should expect MDACC
usage to surpass the usage estimated by a model based solely on
its FDA indication. However, building a model to incorporate all
possible uses, without controlling its prescribing, is an impossi-
bility, so we base our models on the FDA-indication(s) for the
drug. Patient outcomes for non-FDA approved usages should be
captured in prospective clinical trials, and included in the model
when they can be quantiﬁed.
A structured formulary management process, which includes
an economic impact analysis section, is an appropriate platform
to delineate the cost effectiveness of new oncology products. In
an era of rising costs, coupled with dwindling resources, a coher-
ent plan for the allocation of resources is an imperative for any
institution that strives to provide continued patient care.
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Therapeutics (P&T) Committee
Problem or Issue Addressed: In August 2006, the DoD P&T
Committee made Uniform Formulary (UF) recommendations to
the Director, TRICARE Management Activity (TMA), for the
Antilipidemic-1 therapeutic class. This was the Committee’s most
signiﬁcant recommendation since the inception of the UF for
three reasons: 1) this class is ranked number one in terms of DoD
expenditures (>$500M in ﬁscal year [FY] 2006; 9% of Rx
spend); 2) the joint DoD/Veteran’s Administration (VA) contract
for Zocor (simvastatin), the workhorse statin for the DoD (65%
of total days of statin therapy across the Military Health System
[MHS] in FY 2006), was about to expire; and 3) competition
within the class was about to increase as a result of impending
generic availability of simvastatin.
Goals: The DoD P&T Committee’s overall goal was to identify
a therapeutic mix of Antilipidemic-1 agents that best met the
majority of the clinical needs of the DoD population at the
lowest cost to the MHS. To accomplish this goal, three primary
objectives were identiﬁed: 1) maintain simvastatin as the work-
horse statin and preserve current market share; 2) include an
agent capable of achieving ≥45% LDL reduction, and 3) rec-
ommend non-formulary status for agents not cost-effective rela-
tive to other agents in the class.
Outcome items used in the decision: The 32 CFR Part 199 (Civil-
ian Health and Medical Program of the Uniform Services
[Champus] / TRICARE: Implementation of the Pharmacy Bene-
ﬁts Program) implements section 701 of the National Defense
Authorization Act for FY 2000. This regulation “establishes pro-
cedures for the inclusion of pharmaceutical agents on a UF based
upon the relative clinical effectiveness and relative cost-effec-
tiveness.” Following this guidance, the DoD P&T Committee
makes UF recommendations based upon both an evidence-based
clinical effectiveness review and a cost effectiveness review of
agents within the therapeutic class. Four different cost effective-
ness models were constructed to analyze the relative cost effec-
tiveness of statins capable of achieving ≥45% LDL reduction
[atorvastatin 40 and 80 mg; rosuvastatin 10, 20, and 40 mg; eze-
timibe/simvastatin 10/20, 10/40, and 10/80 mg; and simvastatin
80 mg]:
1) The Annual Cost per 1% LDL Decrease model compared cost
effectiveness of the high % LDL lowering agents on annual
cost per 1% LDL decrease.
2) The Annual Cost per Patient Treated to Goal model com-
pared cost effectiveness of these agents on annual cost per
patient successfully treated to NCEP.
3) The Medical Cost Offset Model compared cost effectiveness
of these agents based on their predicted outcomes and total
predicted health care expenditures for CHD and CHD risk-
equivalent patients.
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4) The Cost per Event-Free Patient model, based on the results
of the IDEAL Trial, compared cost effectiveness of the agents
included in that trial—high-dose (80 mg) atorvastatin vs. low-
dose (20–40 mg) simvastatin.
In addition, a budget impact analysis was performed to assist the
Committee in determining which group of agents best met 
the majority of the clinical needs of the DoD population at the
lowest cost to the MHS.
Implementation Strategy: On 23 October 2006, the Director,
TMA signed a decision paper accepting the DoD P&T Com-
mittee’s Antilipidemic-1 UF recommendations, with an imple-
mentation date of 1 February 2007. Accordingly, atorvastatin,
ﬂuvastatin immediate and extended release, pravastatin, simvas-
tatin, lovastatin immediate & extended release, lovastatin/niacin,
ezetimibe/simvastatin, niacin immediate and extended release,
and ezetimibe were maintained as formulary on the UF and rosu-
vastatin and atorvastatin/amlodipine were classiﬁed as non-for-
mulary under the UF.
Results: The DoD P&T Committee met its primary goal by pro-
viding a broad array of Antilipidemic-1 agents sufﬁcient to meet
the clinical needs for the majority of the DoD population. It also
met two of its primary objectives: 1) two agents were included
on the UF, in addition to simvastatin 80 mg, capable of achiev-
ing ≥45% LDL reduction (atorvastatin and simvastatin/ezetim-
ibe); 2) agents determined not to be cost-effective relative to
other agents in the class were designated as non-formulary on
the UF. Whether or not the DoD is successful in preserving sim-
vastatin market share will be closely monitored as this decision
is implemented.
Lessons Learned: Presentation of results from multiple cost effec-
tiveness models—which focus on different outcomes and use dif-
ferent methods, but are all based on an evidence-based review of
the clinical and pharmacoeconomic literature—increased the
Committee’s conﬁdence in making recommendations in this
class. The BIA, which incorporated factors not included in the
cost effectiveness models, further reﬁned the Committee’s under-
standing of the expected beneﬁts resulting from various formu-
lary scenarios.
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EVALUATION OF LEVALBUTEROL USE IN A >600 BED
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University of Maryland Medical Center, Baltimore, MD, USA
Organization: University of Maryland Medical Center
Problem or Issue Addressed: Excessive use of a high cost non-
formulary drug.
Goal: To evaluate the use of Levalbuterol in a teaching hospital
and to determine need for inclusion (if any) on the hospital 
formulary.
Outcomes items used in the decision: Levalbuterol is FDA-
approved for the treatment or prevention of acute bronchospasm
in adults, adolescents, and children aged 6 or older with
reversible obstructive airway disease. Our institution recently
realized a signiﬁcant increase in the purchasing of this agent,
which prompted an intensive evaluation of the prescribing habits
surrounding levalbuterol. The purpose of our study was to iden-
tify the indications for levalbuterol use, evaluate the appro-
priateness of dosing, determine contraindications to alternate
therapies, and recognize adverse events, if any, associated with
levalbuterol use.
Implementation Strategy: This evaluation was a criteria-based,
retrospective evaluation of all patients for whom levalbuterol
was prescribed over an 18 month period. All patients were iden-
tiﬁed from computerized pharmacy records. Patient therapy was
evaluated via physician progress notes, laboratory reports, and
physician orders. Purchase data was determined via the phar-
macy’s computerized medication inventory management system.
Results: The majority of levalbuterol use was in pediatric
patients (27%), followed by cardiac surgery patients (17%) and
internal medicine service patients (14%). Indications of short-
ness of breath or respiratory distress associated with various
disease states and medical procedures comprised 38% of leval-
buterol use. 35% of use was in COPD (20%) and asthma (15%)
combined. The majority of patients received levalbuterol for <3
days at a dosing frequency of less than every 6 hours. 80% of
patients received albuterol therapy prior to levalbuterol admin-
istration. No adverse events related to levalbuterol use were
reported.
Conclusions/Lessons Learned: Our study reveals that patients
are prescribed levalbuterol for a variety of indications, most of
which are non-FDA approved uses. Patients at high risk for
cardiac side effects, including pediatric and cardiac surgery
patients, are likely to receive levalbuterol. Prescribers typically
utilize levalbuterol after patients failed to improve on or experi-
enced side effects to albuterol. Dosing frequency exceeded
approved labeling and established guidelines in most cases.
Determined there may be a need to include levalbuterol on the
hospital formulary restricted to pediatric patients meeting certain
speciﬁc criteria.
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USING OUTCOMES RESEARCH TO SUPPORT 
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Basskin L
Healthsouth Sunrise Rehab Hospital, Cooper City, FL, USA
Organization: Healthsouth Sunrise Rehabilitation Hospital
Problem or Issue Addressed: Increasing costs of Antibiotics
Goals: To determine the reasons for increased costs of antibiotics
at a rehabilitation hospital, and to determine whether interven-
tions were necessary to reduce costs and improve outcomes.
Outcomes items used in the decision: a) organism susceptibility
per cultures when compared to empiric antibiotics selected; b)
proportion of empiric antibiotics subsequently determined to be
resistant; c) incidence of intravenous medications when patient
was receiving oral medications; d) duration of antibiotic therapy
when patient was asymptomatic (and compared to recom-
mended duration of therapy); and e) appropriate dose and inter-
val based on patient’s renal function.
Implementation Strategy: Random sampling of patients receiv-
ing antibiotics used in the previous 12 months.
Results: 1. More cost-effective medication were available empir-
ically in the treatment of UTI and Cellulitus. 2. Selection of resis-
tant antibiotics occurred infrequently, but when encountered, the
change in antibiotics was delayed at times. 3. Some asympto-
matic patients who were receiving all other medications oral
could have been switched from IV to PO antibiotics. 4. Some
excess duration because of antibiotic use at prior facility. 5. Dose
and interval appropriate with some adjustments require for renal
function, readily accepted by physicians.
Conclusions/Lessons Learned: Antibiotic selection needs some
intervention. Three part program will be implemented: 1. Some
restrictions on availability of ordering IV antibiotics without ID
consult. 2. Physician education as to proper dose, interval, and
frequency. 3. A pharmacy-run infectious disease service to guide
empiric selection and ensure quick review of cultures.
